Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (11674)	11/17/2012 3:41:38 PM
From: NTTG	3 Recommendations Read Replies (1) \| Respond to of 13111

You are obviously new here and not up to speed, so we wont waste air time on homework you have yet to do. Look at data from original PII reports, read recent PRs on discussions with the FDA about patent populations and dosing (all a matter of public record, not FDA insider stuff) and get on board with what is happening to the study design. Stage III non aggressive disease patients probably respond well to conventional therapy, not that you will know that for another 3-4 years. My comment about MGT refers to the management of this board, I have been banned twice for voicing direct and unpopular views, and have been explicitly warned not to discuss the veracity of statements from the blog site, apparently someone gets whinny when I do. The views of concern relate to my interpretations of PVCT corporate performance, and posts on other company activities as comparative examples....You can read more on the progress of others at the YAHOO board.